Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Persistent Disease Clear all
Completed Phase 4 Interventional Results available

Prevention of Persistent Opioid Use in Mothers

NCT03472521
View directory record Official record
Conditions
Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

NCT00687687
View directory record Official record
Conditions
Uterine Carcinosarcoma
Interventions
paclitaxel, carboplatin, BSI-201 (Iniparib)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
40
States / cities
Aurora, Colorado • Englewood, Colorado • New Britain, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

NCT00534118
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
donor lymphocytes
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 76 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

A Study for the Treatment of Painful Diabetic Neuropathy

NCT00058968
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pembroke Pines, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)

NCT00085332
View directory record Official record
Conditions
Endometrial Cancer
Interventions
docetaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jul 21, 2026, 10:10 PM EDT
Active, not recruiting No phase listed Observational

STOP Persistent AF PAS

NCT05005949
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Arctic Front™ Cardiac Cryoablation Catheter System
Device
Lead sponsor
Medtronic Cardiac Ablation Solutions
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Hartford, Connecticut • Stamford, Connecticut • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

NCT01386554
View directory record Official record
Conditions
Proteinuria, Idiopathic Membranous Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00132067
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
vorinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Terminated Not applicable Interventional

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

NCT01683045
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
The Estech COBRA® Surgical System
Device
Lead sponsor
Endoscopic Technologies, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Mesa, Arizona • Hartford, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease

NCT00001528
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 10:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Project 4A: Inspiratory Muscle Training and Diaphragm Strength

NCT02367170
View directory record Official record
Conditions
Sepsis
Interventions
Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples
Procedure · Drug · Device + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 21, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

NCT01409031
View directory record Official record
Conditions
Persistent Pulmonary Hypertension, Respiratory Failure
Interventions
Intravenous Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00574951
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
motesanib diphosphate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
19
States / cities
Burbank, California • New Britain, Connecticut • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion

NCT05270083
View directory record Official record
Conditions
Concussion, Brain
Interventions
NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

NCT06159725
View directory record Official record
Conditions
Persistent Infection, Cystic Fibrosis
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00872989
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
docetaxel, vandetanib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
137
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational

Feasibility and Acceptability of the Propeller Monitoring System in Children With Persistent Asthma

NCT03648450
View directory record Official record
Conditions
Asthma
Interventions
Propeller EMD
Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
10 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

NCT03448081
View directory record Official record
Conditions
Pruritus, Psoriasis
Interventions
SNA-120, Placebo, Calcipotriene
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

NCT02440425
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Pembrolizumab, Paclitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01039207
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Rilotumumab
Other · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
Burbank, California • New Britain, Connecticut • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076399
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 21, 2026, 10:10 PM EDT